HealthAdvance Fund


Tuberculosis is characterized by 10 million cases and 1.5 million deaths per year. New drugs are needed to reduce treatment duration and to treat drug-resistant infections. We propose a solution based on our preclinical drug lead (JSF-3285) that inhibits the essential ß-ketoacyl synthase and exhibits promising efficacy and safety profiles. 

Cellular level image

The research team is developing a Cryptococcus fungal vaccine (HK-fbp1) that has shown cross protection against multiple major invasive mycoses, including Cryptococcus species, Aspergillus fumigatus, and Candida albicans. Its protection remains effective against Cryptococcus and Aspergillus in certain immunocompromised hosts, such as CD4 T cell-depleted mice, a condition mimicking AIDS patients.